Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102433 | 0.87 | KDM4E (0.59) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL9090050 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL7274828 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL118201 | 0.85 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL1202722 | 0.84 | KDM4E (0.55) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL8190856 | 0.84 | KDM4E (0.55) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL118914 | 0.84 | KDM4E (0.55) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL29469813 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL24857536 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1HPGDPOLBCYP1A2 | |
| SCHEMBL8197387 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1HPGDPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4213843-B1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024222712-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024218059-A1 | NEW α4β7 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2024-10-24 | — | — | WO | disclosed |
| CN-118515663-A | Imidazopyridine or imidazopyrazine compounds, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240059680-A1 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-22 | — | — | US | disclosed |
| US-20240018140-A1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-8546440-B2 | Substituted bicyclic imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546440-B2 | Substituted bicyclic imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2424866-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. | 2011-09-29 | — | — | US | disclosed |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. | 2011-09-29 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | KDM4E 2988/4885ALDH1A1 1842/4885HPGD 1574/4885 |
| US-20240059680-A1 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | TNNT2, TNNI3, SIRT5 | KDM4E 837/4885ALDH1A1 491/4885HPGD 650/4885 |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | KDM4E 2967/4885ALDH1A1 2155/4885HPGD 2417/4885 |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | KDM4E 2159/4885ALDH1A1 2320/4885HPGD 2267/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | KDM4E 3905/4885ALDH1A1 1430/4885HPGD 1510/4885 |
| US-20240018140-A1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | KDM4E 3855/4885ALDH1A1 1745/4885HPGD 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.